Endocrinology Advisor7d
REDEFINE 1 Trial: Superior Weight Loss Seen With CagriSema
Topline data were announced from a phase 3 trial evaluating CagriSema in overweight or obese patients without type 2 diabetes ...
Novo Nordisk Needs Answers to These 5 Key Questions
Novo Nordisk shares fell 30% in the fourth quarter on disappointing clinical trial data, concerns about its experimental ...
STAT19d
What Novo Nordisk’s disappointing trial results mean for the obesity drug market
New clinical trial data from Novo Nordisk raise questions for the broad landscape of obesity drug development and the way ...
Ozempic maker Novo Nordisk, after trial disappointment, expands AI deal in potential $4.6 billion pact
At least four analysts weighed in on the prospects for Europe’s second-largest company, Novo Nordisk, after the Danish drugmaker reported disappointing results for its next-generation weight-loss drug ...
Novo Nordisk expands AI partnership with Valo Health for development of obesity drugs
Novo's drug candidate, CagriSema, showed weight loss below expectations during a trial, dealing a blow to the company's plans ...
The Motley Fool on MSN7d
Should You Buy the Dip in Novo Nordisk Stock Right Now?
Right now, Novo stock is trading at a forward price-to-earnings (P/E) multiple of 22.5 -- its lowest level in well over a ...
FiercePharma23h
Launches from Novo, Lilly top Clarivate's annual 'Drugs to Watch' list
If innovative cancer therapies were the top launches to watch in 2024, this year’s high-profile biopharma debuts is slated to ...
Jim Cramer: Lemonade Is 'Up Too Much,' This Health Care Stock Can Go Lower
JMP Securities analyst Ronald Josey maintained Lemonade with a Market Outperform and raised the price target from $40 to $60.
labiotech1d
Ten drugs to watch in 2025: will these therapies become blockbusters?
A blockbuster drug is a therapy that generates at least $1 billion in sales. Clarivate’s Drugs to Watch 2025 report includes ...
Newsable Asianet News on MSN1d
Denmark's Novo Nordisk Rebounds Pre-Market On UBS Upgrade, But Trump's Tariff Threats Over Greenland Leaves Retail Uneasy
Novo Nordisk shares climbed over 3% in Wednesday's pre-market trading as U.S. stock futures rebounded from a tech-driven ...
Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst
JPMorgan highlights valuation resets for Viking and Structure Therapeutics, citing opportunities in T2D/obesity and competitive clinical data insights.